## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.7% below STRENGTH zone (4.0-10.0%); PEG 2.21 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($116.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Citigroup Begins Coverage on Ducommun (NYSE:DCO)**
- Source: MarketBeat | 20251214T140938 | Neutral | Relevance: 63%
- Citigroup has initiated coverage on Ducommun (NYSE:DCO) with a "Buy" rating, supporting the "Moderate Buy" consensus and a target price of $99.75 among analysts. Despite slightly exceeding Q3 EPS expectations and a 5.6% revenue increase year-over-year, Ducommun faces negative net margins and PE ratio while trading near its 52-week high. Insiders own 8.90% and institutional investors hold 92.15% of the shares, with a recent insider stock sale noted.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |
| 2025-11-18 | Stifel | $130 | $140 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |
| 2025-11-18 | Stifel | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 17.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +6.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.21 elevated, pricing in significant growth expectations. Forward P/E 18.2x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.6B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.21 |
| Forward P/E | 18.2 |
| Current P/E | 19.4 |
| YoY Growth | 7.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.1% to 1.7% (+6.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 at 3.9% confirms short-term momentum alignment. Below SMA200 (0.82x), long-term trend not supportive. MACD histogram positive (0.69), confirming momentum. RSI neutral at 49. Elevated volume (2.0x 20MA), institutional activity likely. OFD pattern: +SBH (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.70% (CS: 58) | Neutral |
| RSI_14 | 49.4 | Neutral |
| MACD Histogram | 0.69 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 0.945x | Below |
| vs SMA200 | 0.824x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.24
- **Stop Loss:** $116.52 (5.5% risk)
- **Target:** $129.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 148
- **Position Value:** $18,239.52
- **Portfolio %:** 18.24%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*